Pfizer Post-Mortem – Another One Bites the Dust
True to my dividend investing code, I have sold Pfizer after their recently announced 50% dividend cut to offset the purchase of Wyeth. Pfizer has been a stock that I have held for a long time, and held great faith in the company as a strong dividend growth company. However this changed quickly and the stock is no longer a component of my dividend portfolio.[ad#tdg-embedded] As I do with every stock holding that I own does not work out the way I planned I thought back to why I was holding …
Continue Reading about Pfizer Post-Mortem – Another One Bites the Dust